Little Chesterford, United Kingdom

Rachel E Lill

This inventor holds 1 USPTO granted patent. Top assignee: Biotica Technology Limited. Active years: 2010.


Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rachel E Lill: Innovator in Erythromycin Development

Introduction

Rachel E Lill is a prominent inventor based in Little Chesterford, GB. She has made significant contributions to the field of pharmaceuticals, particularly in the development of erythromycins. Her innovative work has led to advancements in the preparation of 14-membered macrolide compounds.

Latest Patents

Rachel E Lill holds 1 patent for her invention titled "Erythromycins and process for their preparation." This patent focuses on providing functional groups at the 14- and/or 15-position of erythromycins by utilizing a 14-membered aglycone template. The process involves feeding this template to a strain capable of hydroxylating it at the specified positions. The strain can be identified through screening, selected from known strains such as DSM 40014, or produced by genetically engineering a strain to express a cytochrome P450 enzyme.

Career Highlights

Rachel is associated with Biotica Technology Limited, where she continues to push the boundaries of pharmaceutical innovation. Her work has been instrumental in enhancing the efficacy of erythromycins, which are crucial in treating various bacterial infections.

Collaborations

Rachel collaborates with Steven Gary Kendrew, leveraging their combined expertise to further their research and development efforts in the field of macrolide compounds.

Conclusion

Rachel E Lill's contributions to the field of erythromycin development exemplify her dedication to innovation in pharmaceuticals. Her work not only advances scientific knowledge but also has the potential to improve therapeutic outcomes for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…